AKT1 and breast carcinoma: One recent publication on p-Akt in relation to the clinical benefit of paclitaxel in the adjuvant treatment of breast cancer recognised the potential for loss of immunoreactivity because of variations in specimen fixation; an optimised antigen retrieval technique was stated to have been used, but its effectiveness was not reported [20].